Previous Close | 0.0079 |
Open | 0.0060 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0060 - 0.0060 |
52 Week Range | 0.0030 - 0.0521 |
Volume | |
Avg. Volume | 15,260 |
Market Cap | 716,286 |
Beta (5Y Monthly) | 0.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
PsyBio continues to develop psycho-targeted, biosynthesized tryptamines and with this authorization becomes the first biotechnology company to obtain government sanctioned, formal, written authorization to manufacture biosynthetic tryptamines including PsyBio-11142 at scale Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - July 21, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon disco
Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - April 20, 2023) - PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel psycho-targeted therapeutics being designed to improve mental health and neurological conditions, is pleased to announce that the Company has completed the third tranche of its previously announced non-brokered private placement offering of uni